Media keeps delivering like clockwork, 18% organic growth in Q2 We remove Platform and Sportsbook fr...
We cut '24e-'26e EBITDA by 17-9% Still expect meaningful share of hardware-related sales NTM EV/EBIT...
Redeye estimates an 85% probability of the Neonode side settling against Samsung in mid-2025, which ...
Även om Cell impacts utveckling går långsammare än vi tidigare prognosticerat bedömer vi att Cell Im...
Loihde’s Q2 was better than estimated, profitability in particular, with adj.
Kvällen den 27 augusti offentliggjorde edyoutec sin delårsrapport för kv2 2024.
Redeye returns with an update following Alzecure's Q2 report and recent activities in the company.
Nettoomsättningen i det andra kvartalet uppgick till 202,7 MSEK (203,9), en minskning med cirka 0,6 ...
First Venture Sweden (”First Venture” eller ”Bolaget”) är ett investmentbolag med fokus på snabbväxa...
Redeye comments on GiG’s Q2 results, which were overall close to our forecast although Media was str...
Active Biotechs samarbete i USA kring tasquinimod har påbörjat rekrytering till en fas 2-studie inom...
Redeye’s initial take on Xbrane’s Q2 report is that end-customer sales and profit split were higher ...
Redeye updates its view on Lifecare following the Q2 report and recent company developments, includi...
After initiating dosing of the first patient in June with Nanexa’s long-acting depot formulation of ...
Redeye comments on Lipigon's Q2 report 2024. The most significant event since our last update was th...
Weak Q2 margin of 5.0% (7.3%), but book-to-bill improved to 0.
Prostatype Genomics har nyligen lanserat sitt test Prostatype® på den viktiga amerikanska marknaden ...
Mendus’s Q224 results reflect a period of steady progress across its clinical programmes.
TCECUR Sweden AB (”TCECUR” eller ”Koncernen”) har publicerat Koncernens delårsrapport för det andra ...
Redeye leaves a comment relating to the announcement of Werfen and its new POC system GEM Premier 70...
